Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

BISACODYL

Form:

5 of 5 products shown

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (A06A, A06AB) — coverage varies; not interchangeable

  • Citric acid + oxide + picosulfate (Pico-Salax): general benefit
  • Docusate dioctyl sulfosuccinate (Docusate Sodium): general benefit
  • Citrus fibre + grain (Novo-Fibre): general benefit, Not a benefit
  • Lactulose (PMS-Lactulose): general benefit
  • Mineral oil (Fleet Enema Mineral Oil): general benefit

Dulcolax · DIN 00254142 · 5mg · enteric-coated tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Dulcolax · DIN 00254142 Manufacturer: Sanofi Consumer Health Inc.; listing date 1996-10-01 Health Canada: Marketed since 2026-08-24 · brand DULCOLAX · ATC A06AB02 BISACODYL · form Tablet (enteric-coated) · route Oral · ingredients BISACODYL 5 MG · company Opella canada inc. · schedule Non-prescription drugs
Check this DIN again · Health Canada product record

Dulcolax: Formulary list price $0.2009/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2009 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1553 · Verify on the e-Formulary ↗ (DIN 00254142)

Source record
DIN 00254142: Dulcolax Raw flags: sec3=Y, selfMed=Y Item: 561200001; group id 648; item number 1627; lccId None; manufacturer id SCO Source form: Ent Tab; strength: 5mg Recorded listing: General benefit; self-medication (OTC-type) product Source prices (unrounded): $0.2009; ministry $0.2009 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00254142 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1553
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00254142
Shortage record checked 2026-09-13T08:10:21.292534+00:00

AMB-Bisacodyl · DIN 02520478 · 10mg · suppository

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
AMB-Bisacodyl · DIN 02520478 Manufacturer: Ambicare Pharmaceuticals Inc.; listing date 2025-06-30 Health Canada: Marketed since 2024-06-03 · brand AMB-BISACODYL · ATC A06AB02 BISACODYL · form Suppository · route Rectal · ingredients BISACODYL 10 MG · company Ambicare pharmaceuticals inc. · schedule Non-prescription drugs
Check this DIN again · Health Canada product record

AMB-Bisacodyl: Formulary list price $0.4206/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4206 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100967 · Verify on the e-Formulary ↗ (DIN 02520478)

Source record
DIN 02520478: AMB-Bisacodyl Raw flags: sec3=Y, selfMed=Y Item: 561200002; group id 648; item number 1628; lccId None; manufacturer id AMB Source form: Sup; strength: 10mg Recorded listing: General benefit; self-medication (OTC-type) product Source prices (unrounded): $0.4206; ministry $0.4206 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02520478 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100967
Interchangeable products
Bisacodyl 10mg · DIN 02458853 · $0.4206 Bisacodyl Suppository · DIN 02361450 · $0.4206 Dulcolax · DIN 00003875 · $0.4206
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02520478
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Bisacodyl Suppository · DIN 02361450 · 10mg · suppository

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Bisacodyl Suppository · DIN 02361450 Manufacturer: Jamp Pharma Corporation; listing date 2022-04-29 Health Canada: Marketed since 2014-01-30 · brand BISACODYL SUPPOSITORY · ATC A06AB02 BISACODYL · form Suppository · route Rectal · ingredients BISACODYL 10 MG · company Jamp pharma corporation · schedule Non-prescription drugs
Check this DIN again · Health Canada product record

Bisacodyl Suppository: Formulary list price $0.4206/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4206 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84651 · Verify on the e-Formulary ↗ (DIN 02361450)

Source record
DIN 02361450: Bisacodyl Suppository Raw flags: sec3=Y, selfMed=Y Item: 561200002; group id 648; item number 1628; lccId None; manufacturer id JPC Source form: Sup; strength: 10mg Recorded listing: General benefit; self-medication (OTC-type) product Source prices (unrounded): $0.4206; ministry $0.4206 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02361450 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84651
Interchangeable products
AMB-Bisacodyl · DIN 02520478 · $0.4206 Bisacodyl 10mg · DIN 02458853 · $0.4206 Dulcolax · DIN 00003875 · $0.4206
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02361450
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Dulcolax · DIN 00003875 · 10mg · suppository

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Dulcolax · DIN 00003875 Manufacturer: Sanofi Consumer Health Inc.; listing date 1996-10-01 Health Canada: Marketed since 2026-08-24 · brand DULCOLAX · ATC A06AB02 BISACODYL · form Suppository · route Rectal · ingredients BISACODYL 10 MG · company Opella canada inc. · schedule Non-prescription drugs
Check this DIN again · Health Canada product record

Ministry pays: $0.4206 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1555 · Verify on the e-Formulary ↗ (DIN 00003875)

Source record
DIN 00003875: Dulcolax Raw flags: sec3=Y, selfMed=Y Item: 561200002; group id 648; item number 1628; lccId None; manufacturer id SCO Source form: Sup; strength: 10mg Recorded listing: General benefit; self-medication (OTC-type) product Source prices (unrounded): $1.2267; ministry $0.4206 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00003875 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1555
Interchangeable products
AMB-Bisacodyl · DIN 02520478 · $0.4206 Bisacodyl 10mg · DIN 02458853 · $0.4206 Bisacodyl Suppository · DIN 02361450 · $0.4206
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00003875
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Bisacodyl 10mg · DIN 02458853 · 10mg · suppository

General benefitDormant since 2021-07-14 · checked 2026-09-02 · What does dormant mean?
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Bisacodyl 10mg · DIN 02458853 Manufacturer: CellChem Pharmaceuticals Inc.; listing date 2020-08-28 Health Canada: Dormant since 2021-07-14 · brand BISACODYL 10 MG · ATC A06AB02 BISACODYL · form Suppository · route Rectal · ingredients BISACODYL 10 MG · company Cellchem pharmaceuticals inc. · schedule Non-prescription drugs
Check this DIN again · Health Canada product record

Bisacodyl 10mg: Formulary list price $0.4206/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4206 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94603 · Verify on the e-Formulary ↗ (DIN 02458853)

Source record
DIN 02458853: Bisacodyl 10mg Raw flags: sec3=Y, selfMed=Y Item: 561200002; group id 648; item number 1628; lccId None; manufacturer id CCP Source form: Sup; strength: 10mg Recorded listing: General benefit; self-medication (OTC-type) product Source prices (unrounded): $0.4206; ministry $0.4206 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02458853 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94603
Interchangeable products
AMB-Bisacodyl · DIN 02520478 · $0.4206 Bisacodyl Suppository · DIN 02361450 · $0.4206 Dulcolax · DIN 00003875 · $0.4206
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02458853
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2021-07-14 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (56:12 Cathartics) and how they are covered

Matched class: 56:12 Cathartics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DOCUSATE SODIUM (DIOCTYL SODIUM SULFOSUCCINATE), LACTULOSE, MAGNESIUM OXIDE & CITRIC ACID & SODIUM PICOSULFATE, MINERAL OIL, PSYLLIUM MUCILLOID, SENNOSIDES A & B, SODIUM BIPHOSPHATE & SODIUM PHOSPHATE Some products covered without a code (check the product listing): GRAIN & CITRUS FIBRE 56:12 Cathartics

MAGNESIUM OXIDE & CITRIC ACID & SODIUM PICOSULFATE

· 2 products · General benefit · strengths: 3.5g & 12g & 10mg · Pd for Sol-12g Sachet

DOCUSATE SODIUM (DIOCTYL SODIUM SULFOSUCCINATE)

· 6 products · General benefit · strengths: 100mg, 4mg/mL, 10mg/mL · Cap, O/L

GRAIN & CITRUS FIBRE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: · Tab

LACTULOSE

· 1 products · General benefit · strengths: 667mg/mL · O/L

MINERAL OIL

· 1 products · General benefit · strengths: 100% · Enema

PSYLLIUM MUCILLOID

· 1 products · General benefit · strengths: · Oral Pd

SENNOSIDES A & B

· 2 products · General benefit · strengths: 8.6mg · Tab

SODIUM BIPHOSPHATE & SODIUM PHOSPHATE

· 2 products · General benefit · strengths: 160mg & 60mg/mL · Ped Rect Sol, Rect Sol (with Preservative) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 56:12
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:16 Digestants, 56:22 Antiemetics and Antinauseants, 56:40 Miscellaneous G.I. Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: constipation
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. PEG-ELECTROLYTES · Listed, not a benefit (1), General benefit (2) INDICATIONS AND CLINICAL USE Adults Colyte® (PEG 3350 and Electrolytes) is indicated for:  bowel cleansing prior to colonoscopy or barium enema x-ray examination or surgical procedures requiring a clean colon.  the treatment of constipation PM: https://pdf.hres.ca/dpd_pm/00061814.PDF; date March 25, 2021; DIN 00677442; fetched 2026-09-10 Product monograph PRUCALOPRIDE · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS RESOTRAN® (prucalopride succinate tablets) is indicated for: • The treatment of chronic idiopathic constipation in adult female patients in whom laxatives failed to provide adequate relief. PM: https://pdf.hres.ca/dpd_pm/00073288.PDF; date NOV 08, 2023; DIN 02377012; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE DULCOLAX is indicated for: • Relief of occasional constipation • Under medical supervision, for the preparation of diagnostic procedures, in pre- and postoperative treatment, and in conditions which require defecation to be facilitated. https://pdf.hres.ca/dpd_pm/00076868.PDF PM date: November 3, 2022 Source product: DULCOLAX; DIN 00003875; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)